The usage and effectiveness of NST are on the rise, with high pathological complete response (pCR) rates observed, particularly in patients with triple-negative (TN) and HER2-positive breast cancer.1–3 It remains unclear whether breast surgery contributes to local control and survival in patients who achieve pCR. The gene discussed is ERBB2; the disease is breast carcinoma.